Cargando…

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

PURPOSE: Previous cohort studies have reported plasma TK1 activity (pTKa) as a potential prognostic biomarker in estrogen receptor-positive (ER+) HER2-negative (HER2−) metastatic breast cancer (MBC). In this prospective study, we report here the prognostic impact of pTKa in ER+/HER2− MBC patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cabel, Luc, Rosenblum, Dan, Lerebours, Florence, Brain, Etienne, Loirat, Delphine, Bergqvist, Mattias, Cottu, Paul, Donnadieu, Anne, Bethune, Anne, Kiavue, Nicolas, Rodrigues, Manuel, Pierga, Jean-Yves, Tanguy, Marie-Laure, Bidard, François-Clément
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489000/ https://www.ncbi.nlm.nih.gov/pubmed/32928264 http://dx.doi.org/10.1186/s13058-020-01334-2

Ejemplares similares

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
por: Cabel, Luc, et al.
Publicado: (2021)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
por: Darrigues, Lauren, et al.
Publicado: (2021)

Clinical utility of circulating tumor cells: an update
por: Vasseur, Antoine, et al.
Publicado: (2020)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy
por: Bonechi, Martina, et al.
Publicado: (2018)

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2017)

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023)

Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals
por: Chalumeau, Clelia, et al.
Publicado: (2022)

ESR1 Mutation Detection and Dynamics in Meningeal Carcinomatosis in Breast Cancer
por: Carausu, Marcela, et al.
Publicado: (2019)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
por: Bagegni, Nusayba, et al.
Publicado: (2017)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER(+)/HER2(−) Breast Cancer
por: Dowsett, Mitch, et al.
Publicado: (2022)

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
por: Bidard, François-Clément, et al.
Publicado: (2012)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
por: Berger, Frédérique, et al.
Publicado: (2022)

Circulating Tumor Cells in Early Breast Cancer
por: Thery, Laura, et al.
Publicado: (2019)

Efficacy and safety of palbociclib plus endocrine therapy for patients with HR(+)/HER2(−) advanced breast cancer in real-world clinical practice
por: Zhong, Bingqian, et al.
Publicado: (2022)

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
por: Vuagnat, Perrine, et al.
Publicado: (2020)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
por: Demir, Atakan, et al.
Publicado: (2020)

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
por: Schettini, Francesco, et al.
Publicado: (2020)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?
por: McCartney, Amelia, et al.
Publicado: (2018)

Quantitative CT Extent of Lung Damage in COVID-19 Pneumonia Is an Independent Risk Factor for Inpatient Mortality in a Population of Cancer Patients: A Prospective Study
por: Ramtohul, Toulsie, et al.
Publicado: (2020)

Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature
por: Beddok, Arnaud, et al.
Publicado: (2020)

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
por: Larsson, Anna-Maria, et al.
Publicado: (2020)

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
por: Tulukcuoglu Guneri, Ezgi, et al.
Publicado: (2022)

Palbociclib combined with endocrine therapy in heavily pretreated HR(+)/HER2(-) advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)
por: Manso, Luis, et al.
Publicado: (2020)

Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population
por: Zhang, Yusi, et al.
Publicado: (2022)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
por: Yang, Jiao, et al.
Publicado: (2023)

Evaluation of serum thymidine kinase 1 activity as a biomarker for treatment effectiveness and prediction of relapse in dogs with non‐Hodgkin lymphoma
por: Boyé, Pierre, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g05f08ghdpec37ci4er4nriefr